ACTIVE INGREDIENT: Ondansetron (as hydrochloride dihydrate)
STRENGTH, PACK SIZE & GMS CODES:
2mg/ml Solution for Injection or Infusion 4mg/2ml x 5
4 mg Film-Coated Tablets x 30 ~ 55314
8 mg Film-Coated Tablets x 10 ~ 55327
8 mg Film-Coated Tablets x 30 ~ 55343
Management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy.
Prevention of postoperative nausea and vomiting (PONV).
For treatment of established PONV, administration by injection is recommended.
Management of chemotherapy-induced nausea and vomiting (CINV) in children aged ≥6 months.
No studies have been conducted on the use of orally administered ondansetron in the prevention and treatment of PONV in children aged ≥1 month, administration by IV injection is recommended for this purpose.